Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website https://www.cardiologyres.org

Short Communication

Volume 12, Number 6, December 2021, pages 358-362


A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients

Figure

Figure 1.
Figure 1. Changes in eGFR (a) and serum uric acid (b) after the switching from fenofibrate to pemafibrate in type 2 diabetic patients. Black circles and error bars indicate mean and SD, respectively. *P < 0.05 vs. values at baseline. eGFR: estimated glomerular filtration rate; SD: standard deviation.

Tables

Table 1. Characteristics for Type 2 Diabetic Patients Who Had Undergone the Switching From Fenofibrate to Pemafibrate (n = 15
 
Characteristics
SD: standard deviation.
Clinical characteristics
  Age (years)55.1 ± 12.0
  Gender (male/female)8/7
  Body weight (mean ± SD, kg)75.2 ± 15.6
  Body mass index (mean ± SD, kg/m2)27.5 ± 4.8
  Systolic blood pressure (mean ± SD, mm Hg)133.4 ± 12.7
  Diastolic blood pressure (mean ± SD, mm Hg)79.4 ± 11.2
Treatments for type 2 diabetes
  Dipeptidyl peptidase-4 inhibitors (n)4
  Metformin (n)7
  Sodium-glucose co-transporter 2 inhibitors (n)8
  Glucagon-like peptide 1 receptor agonists (n)3
  Sulfonylurea (n)1
  Insulin (n)2
  α-glucosidase inhibitors (n)1
Treatments for hypertension
  Angiotensin receptor blockers (n)8
  Calcium antagonists (n)6
  Diuretics (n)2
  β-blockers (n)1
  Mineralocorticoid receptor antagonist (n)1
Treatments for dyslipidemia
  Statins (n)2
  Ezetimibe (n)6

 

Table 2. Changes in Metabolic Parameters After Switching From Fenofibrate to Pemabibrate
 
BaselineAfter 3 monthsAfter 6 monthsAfter 12 months
*P < 0.05 vs. baseline.
Aspartate aminotransferase (IU/L)79.1 ± 194.163.6 ± 148.434.4 ± 35.726.7 ± 8.5
Alanine aminotransferase (IU/L)37.4 ± 31.131.1 ± 20.927.8 ± 18.6*34.7 ± 27.1
γ-glutamyl transpeptidase (IU/L)144.8 ± 319.883.4 ± 140.794.2 ± 160.992.0 ± 154.8
Creatine phosphokinase (IU/L)100.1 ± 72.4110.2 ± 64.2100.6 ± 37.5136.3 ± 139.5
Plasma glucose (mg/dL)148.9 ± 42.9164.6 ± 53.1150.1 ± 34.4162.5 ± 41.6
HbA1c (%)7.0 ± 1.26.9 ± 0.96.8 ± 0.86.9 ± 0.8
Total cholesterol (mg/dL)216.7 ± 70.3201.4 ± 34.2191.4 ± 15.4186.1 ± 30.8
Triglyceride (mg/dL)346.3 ± 468.5314.3 ± 335.8203.9 ± 105.4217.5 ± 123.0
HDL-cholesterol (mg/dL)55.5 ± 27.547.4 ± 10.147.8 ± 10.851.7 ± 11.9
LDL-cholesterol (mg/dL)108.7 ± 18.5112.0 ± 16.9116.8 ± 15.4108.4 ± 26.5
Non-HDL-cholesterol (mg/dL)161.2 ± 72.9154.0 ± 34.3143.6 ± 10.7134.4 ± 30.9